Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409280 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL6409283 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL3019082 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL3019079 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL5695470 | 0.78 | MAPT (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL14288490 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL12364014 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL2261891 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL2261888 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL3801104 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012153125-A1 | NOVEL COMPOUNDS AND METHODS FOR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2012-11-15 | — | — | WO | claimed |
| US-11718686-B2 | Anti-transglutaminase 2 antibodies | LIFEARC (GB) | 2023-08-08 | — | — | US | disclosed |
| WO-2023135425-A1 | INHIBITORS OF TRANSGLUTAMINASE | ASTON UNIVERSITY (GB) | 2023-07-20 | — | — | WO | disclosed |
| EP-3833348-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20210101999-A1 | Anti-Transglutaminase 2 Antibodies | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2021-04-08 | — | — | US | disclosed |
| US-10961319-B2 | Anti-transglutaminase 2 antibodies | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| EP-3521315-B1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LIFEARC (GB) | 2020-10-14 | — | — | EP | disclosed |
| EP-3521315-A1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LifeArc (GB) | 2019-08-07 | — | — | EP | disclosed |
| EP-2855530-B1 | ANTI-TRANSGLUTAMINASE 2 ANTIBODIES | LIFEARC (GB) | 2019-05-01 | — | — | EP | disclosed |
| EP-2906543-B1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | UNIV ASTON (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20050209195-A1 | Indolinone derivatives | CELL THERAPEUTICS EUROPE S.R.I (IT) | 2005-09-22 | — | — | US | disclosed |
| WO-2005068424-A1 | INDOLINONE DERIVATIVES AS RECEPTOR TYROSINE KINASE IHIBITORS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2005-07-28 | — | — | WO | disclosed |
| US-6358750-B1 | FOR COMBINATORIAL LIBRARIES; DRUG SCREENING | ARQULE, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1125937-A2 | Spiro [Pyrrolidine-2,3'-oxindole] compounds and methods of use | ARQULE, INC. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1015430-A4 | SPIRO PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6114540-A | COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-1015430-A1 | SPIRO PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012904-A1 | SPIRO[PYRROLIDINE-2,3'-OXINDOLE] COMPOUNDS AND METHODS OF USE | ARQULE, INC. (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961319-B2 | Anti-transglutaminase 2 antibodies | TGM2, TGM3, TGM6 | SMN1; SMN2 1291/4885MAPT 517/4885ALDH1A1 4213/4885 |
| US-20210101999-A1 | Anti-Transglutaminase 2 Antibodies | TGM2, TGM3, TGM6 | SMN1; SMN2 1291/4885MAPT 517/4885ALDH1A1 4213/4885 |
| US-11718686-B2 | Anti-transglutaminase 2 antibodies | TGM2, TGM3, TGM6 | SMN1; SMN2 1291/4885MAPT 517/4885ALDH1A1 4213/4885 |
| US-20050209195-A1 | Indolinone derivatives | RET, MET, FGFR1 | SMN1; SMN2 4270/4885MAPT 2993/4885ALDH1A1 510/4885 |
| US-20080234267-A1 | Compounds and Methods of Treatment | RET, ABL1, PRKACA | SMN1; SMN2 943/4885MAPT 1914/4885ALDH1A1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.